Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) traded at $38.08, a session gain of 26.5%, as of 11:42 a.m. ET on September 22, 2026, after the company released positive topline results from the maintenance dosing study of its lead GLP-1/GIP agonist VK2735. The move was almost entirely Viking’s own; the rest of the obesity complex barely twitched.
What Viking Reported
Viking’s September 22, 2026, release covers a randomized, double-blind, placebo-controlled trial of VK2735 in adults with obesity. Participants took weekly subcutaneous induction dosing, then transitioned to less frequent maintenance regimens including every-other-week and monthly schedules. CEO Brian Lian previewed the design in July, saying the study “is designed to explore the effects of various maintenance regimens, including monthly and every other week dosing.” The company framed the data as validating multiple maintenance schedules, a commercially significant finding because patient adherence is a well-known weakness of injectable GLP-1s. These are company-reported topline results and have not yet undergone peer review or regulatory review.
Prior Phase 2 work set the bar. VENTURE showed up to 14.7% mean body weight reduction after 13 weekly subcutaneous doses; VENTURE-Oral delivered up to 12.2% at 13 weeks, with up to 80% of subjects reaching at least 10% weight loss.
Obesity Peers Barely Moved
A prior 24/7 Wall St. piece argued a Viking catalyst would lift the wider small-cap obesity basket, naming Structure Therapeutics (NASDAQ: GPCR) as the clearest secondary beneficiary. However, Structure traded at $36.56, down 0.7% on the session, extending a 47.4% year-to-date decline — even with oral aleniglipron showing placebo-adjusted mean weight loss of 16.3% at the 180 mg dose at 44 weeks, and Phase 3 trials ACCOMPLISH-1 and ACCOMPLISH-2 already dosing.
Eli Lilly (NYSE:LLY) added 1.1% to $1,177.43, in line with recent drift. Lilly’s Q2 Mounjaro sales hit $9.94 billion, up 91%, with Zepbound at $4.93 billion, up 46%. Novo Nordisk (NYSE:NVO) slipped 0.7% to $39.54, deepening a 32.5% one-year decline as the company works through list-price cuts of about 50% for Wegovy and 35% for Ozempic effective January 1, 2027. Traders interpreted the move as company-specific validation of a single asset, not a sector-wide signal.
Does This Strengthen the Buyout Case?
Strong data cuts both ways. It hardens Viking’s standalone posture, which already includes $502 million in cash at quarter end and both VANQUISH-1 and VANQUISH-2 fully enrolled. It also raises the price of any transaction. A June 24/7 Wall St. listicle argued Viking had the leverage to wait on its own timeline. Today’s data strengthens that leverage rather than resolving it. No reporting supports acquisition talks.
What to Watch Next
Lian has said oral VK2735 Phase 3 initiation is expected in Q4 2026, positioning it, in his words, to “potentially become the first orally available dual GLP-1/GIP agonist to reach market.” Viking has also flagged an oral maintenance component to follow. Watch the Q4 oral Phase 3 start and the 78-week VANQUISH readouts.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, moderating workshop sessions at regional conventions.
